NASDAQ · EXAI
Healthcare · Biotechnology
$4.84
Up+$0.00 (+0.00%)
Updated Aug 18, 2026, 8:47 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
EXAI does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning EXAI.
EXAI research
Company profile and research snapshot.
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 13, 2024 | Barclays | Equal-Weight | — |
| Aug 9, 2024 | TD Cowen | Hold | — |
| Jul 29, 2024 | Barclays | Overweight | — |
| Jul 9, 2024 | TD Cowen | Buy | — |
| Apr 22, 2024 | Morgan Stanley | Equal-Weight | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Aug 29, 2024
The AI in pharma and biotech market is projected to grow at an 18.8% CAGR, reaching $13.1 billion by 2034. AI is transforming drug discovery and development, accelerating the process and improving patient outcomes.
Zacks Investment Research · Jun 19, 2024
The mean of analysts' price targets for Exscientia (EXAI) points to a 61.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks Investment Research · Jun 3, 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 57.2% in Exscientia (EXAI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks Investment Research · May 23, 2024
Exscientia (EXAI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning EXAI.
No results
No recent SID articles mention EXAI.
